ATAGI recommended COVID-19 vaccine doses¹



For individuals without risk factors²

6 months to 5 years to 18 years to 65 years to 75 years+ 5 years 17 years 64 years 74 years A 2-dose A 2-dose A 2-dose A 2-dose 1. Primary Vaccination is **not** primary course is primary course is primary course is primary course is recommended course recommended recommended recommended recommended 6 months³ 6 months³ 6 months³ A 2023 booster A 2023 booster A 2023 A 2023 2. 2023 booster dose dose is **not** dose should be booster dose is booster dose is (February 2023 guidance) considered⁴ recommended recommended recommended 6 months³ 6 months³ An additional An additional An additional 3. Additional dose dose should be dose is **not** dose is (September 2023 guidance) recommended considered⁴ recommended

Notes:

- 1. Monovalent Omicron XBB.1.5 vaccines are preferred; for ages in which a monovalent XBB.1.5-containing vaccine is not approved, use a vaccine approved for that age group.
- 2. Includes those with a medical condition that increases the risk of severe COVID-19 illness (refer to <u>Australian Immunisation Handbook</u>) or those with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from COVID-19.
- 3. 2023 booster (or additional) dose(s) should be given to eligible individuals from 6 months after their last dose or infection; however where previous infection details are unknown, it is appropriate to proceed with the dose. A person may be vaccinated earlier in exceptional circumstances, such as before starting an immunosuppressant, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
- 4. Consider a booster (or additional) dose based on an individual risk benefit assessment with an immunisation provider.

Information current as of 20 November 2023.

ATAGI recommended COVID-19 vaccine doses¹



For individuals with risk factors²

	6 months to 4 years	5 years to 17 years	18 years to 64 years	65 years to 74 years	75 years+
1. Primary course	A 3-dose primary course is recommended	A 2-dose primary course is recommended ³	A 2-dose primary course is recommended ³	A 2-dose primary course is recommended ³	A 2-dose primary course is recommended ³
		6 months ⁴	6 months ⁴	6 months ⁴	6 months ⁴
2. 2023 booster dose (February 2023 guidance)	A 2023 booster dose is not recommended	A 2023 booster dose should be considered ⁵	A 2023 booster dose is recommended	A 2023 booster dose is recommended	A 2023 booster dose is recommended
			6 months ⁴	6 months ⁴	6 months ⁴
3. Additional 2023 booster dose (September 2023 guidance)		An additional dose is not recommended	An additional dose should be considered ^{5,6}	An additional dose should be considered ⁵	An additional dose is recommended

Notes:

- 1. Monovalent Omicron XBB.1.5 vaccines are preferred; for ages in which a monovalent XBB.1.5-containing vaccine is not approved, use a vaccine approved for that age group.
- 2. Includes those with a medical condition that increases the risk of severe COVID-19 illness (refer to <u>Australian Immunisation Handbook</u>) or those with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from COVID-19.
- 3. A third primary dose is recommended for all people aged 6 months or older with severe immunocompromise who are receiving a 2-dose primary course.
- 4. 2023 booster (or additional) dose(s) should be given to eligible individuals from 6 months after their last dose or infection; however where previous infection details are unknown, it is appropriate to proceed with the dose. A person may be vaccinated earlier in exceptional circumstances, such as before starting an immunosuppressant, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
- 5. Consider a booster (or additional) dose based on an individual risk benefit assessment with an immunisation provider.
- 6. If severely immunocompromised only. Refer to ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised.